Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: A preliminary report of initial experience

Chemotherapy

Volumn 53, Issue 6, 2007, Pages 449-453

  Tanaka, Toshiaki ^a   Fujita, Hiromasa ^a   Sueyoshi, Susumu ^a   Tanaka, Yuichi ^a   Sasahara, Hiroko ^a   Mori, Naoki ^a   Nagano, Tsuyoshi ^a   Yamana, Hideaki ^a   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Esophageal cancer; Second line chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENAL GLAND NEOPLASMS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 36049038526     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110018     Document Type: Article

References (20)

1. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labor and Welfare: Vital statistics of Japan 2004. Tokyo, Ministry of Health, Labor and Welfare, 2006.
2. Fujita H, Sueyoshi S, Tanaka T, Fujii T, Uhi T, Mine T, Sasahara H, Sudo T, Matono S, Yamana H, Shirouzu K: Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 2003;27:571-579.
3. Enzinger PC, Ilson DH, Kelsen DP: Chemotherapy in esophageal cancer. Semin Oncol 1999;26:12-20.
4. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220.
5. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22:172-176.
6. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31:419-423.
7. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-1834.
8. Polee MB, Eskens FALM, van der Burg MEL, Splinter TAW, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A: Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002;86:669-673.
9. Pozzo C, Bugat R, Peschel C: Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophageal junction adenocarcinoma: final results of a randomised phase II study (abstract). Proc ASCO 2001; 20:531.
10. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen DP: A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316-323.
11. Ilson DH, Saitz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, De Groff J, Gonzalez G, Kelsen PD: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17:3270-3275.
12. Laack E, Andritzky B, Durk H, Burkholder I, Edler L, Schuch G, Boeters I, Gorn M, Lipp R, Horst H, Popp J, Hossfeld D: Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie 2005;28:647-650.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke VM, Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
14. Montero A, Fossella F, Hortobagyi G, Valero V: Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-239.
15. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T: A phase II study of docetaxel and infusional cisplatin in advanced non-smallcell lung cancer. Chemotherapy 2005;51:120-125.
16. Balcer-Kubiczek EK, Attarpour M, Jiang J, Kennedy AS, Suntharalingam M: Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy 2006;52:231-240.
17. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-959.
18. Schull B, kornec GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F, Scheithauer W: Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Oncology 2003;65:211-217.
19. Lordick F, von Schilling C, Bernhard H, Henning M, Bredenkamp R, Peschel C: Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003;89:630-633.
20. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Yee, Filho SC, Majlis A, Assadourian S, Cutsem EV: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-5667.